The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor

European Journal of Pharmacology

Volumn 441, Issue 3, 2002, Pages 137-140

  Jordan, Shaun ^a   Koprivica, Vuk ^a   Chen, Ruoyan ^a   Tottori, Katsura ^b   Kikuchi, Tetsuro ^b   Altar, C Anthony ^a  

^a OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

5 HT (5 hydroxytryptomine, seretonin); Aripiprazole (OPC 14597); Dopamine; Partial agonist; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE; SEROTONIN 1 RECEPTOR; SEROTONIN AGONIST; SEROTONIN RECEPTOR; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; BUSPIRONE; CLOZAPINE; DOPAMINE 2 RECEPTOR; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PARTIAL AGONIST; RECOMBINANT RECEPTOR; RISPERIDONE; SEROTONIN; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; ZIPRASIDONE;

ANIMAL; ARTICLE; BINDING SITE; DOSE RESPONSE; HAMSTER; HUMAN; METABOLISM; PHYSIOLOGY; ANIMAL CELL; ANXIETY NEUROSIS; BINDING ASSAY; CELL MEMBRANE; CHO CELL; COGNITION; CONTROLLED STUDY; DEPRESSION; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; NEGATIVE SYNDROME; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; BINDING SITES; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PIPERAZINES; QUINOLONES; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN AGONISTS; ANIMAL; HAMSTERS; HUMAN;

EID: 0037177358     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)01532-7     Document Type: Article

References (19)

1. Prevention by (±)-8-hydroxy-2-(di-n-propylamino)tetralin of both catalepsy and the rises in rat striatal dopamine metabolism caused by haloperidol
2. 2 dopamine receptors
3. Activity of aripiprazole in psychotic disorders: Comparison with haloperidol and placebo
4. Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)- quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland
5. In vivo effects of aripiprazole on dopaminergic and serotonergic function in rat prefrontal cortex and striatum
6. Activity of aripiprazole in psychotic disorders: Comparison with haloperidol and placebo
7. 2 receptor antagonistic activity
8. Interactions of (+)- and (-)-8- and 7-hydroxy-2-(di-n-propylamino)tetralin at human (h)D3, hD2 and h serotonin1A receptors and their modulation of the activity of serotoninergic and dopaminergic neurones in rats
9. Reversal of neuroleptic-induced catalepsy by novel aryl-piperazine anxiolytic drugs
10. The role of serotonin in antipsychotic drug action
11. Improving the treatment of schizophrenia: Focus on serotonin (5-HT)1A receptors
12. Effect of gepirone and ipsapirone on the stimulated and unstimulated secretion of prolactin in the rat
13. Clozapine is a partial agonist at cloned, human serotonin 5-HT1A receptors
14. Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors
15. 35S]GTP gamma S binding by 5-HT1A receptor agonists in recombinant cell lines. Modulation of apparent activity by G-protein activation state
16. Interactions between neuroleptics and 5-HT(1A) ligands in preclinical behavioral models for antipsychotic and extrapyramidal effects
17. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds
18. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding
19. Antipsychotic drug doses and neuroleptic/dopamine receptors